Abstract
Atomwise, a specialist in applying artificial intelligence (AI) to small-molecule drug discovery, will collaborate with South Korea’s Bridge Biotherapeutics on up to 13 molecules in multiple therapeutic areas. Atomwise will use its structure-based AI technology to initiate programs for Pellino E3 ubiquitin ligases and other targets nominated by Bridge. Atomwise will receive unspecified up-front payments, as well as milestone and royalty payments that could top $1 billion.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
